-
Eli Lilly, Boehringer Ingelheim announce linagliptin trial results
INDIANAPOLIS — A drug currently under clinical development for Type 2 diabetes produced "meaningful" reductions in blood sugar, according to results of a late-stage clinical study.
Eli Lilly & Co. and Boehringer Ingelheim announced results of a 24-week, open-label arm of a phase-3 study of the investigational drug linagliptin combined with the generic drug metformin, presenting results at the International Diabetes Federation World Diabetes Conference in Dubai.
-
Report finds retail in holding pattern, identifies major trends
NEW YORK — The retail sector continues to tentatively edge toward recovery, buoyed by a strong start to the holiday shopping season; but several obstacles stand in the way of sustained progress in 2012, according to Jones Lang LaSalle’s "North America Year-end Retail Outlook."